Effects of hormone replacement therapy on cerebral serotonin-1A receptor binding in postmenopausal women examined with [carbonyl-11C]WAY-100635

Georg Kranz, C. Rami-Mark, U. Kaufmann, P. Baldinger, A. Hahn, A. Höflich, M. Savli, P. Stein, W. Wadsak, M. Mitterhauser, D. Winkler, R. Lanzenberger, S. Kasper

Research output: Journal article publicationJournal articleAcademic researchpeer-review

14 Citations (Scopus)

Abstract

Preclinical research points to a strong modulatory influence of gonadal hormones on the serotonin system. However, human data corroborating this association remains scarce. The aim of this study was to examine the effects of hormone replacement therapy on 5-HT1A receptor binding in postmenopausal women using positron emission tomography (PET) and the radioligand [carbonyl-11C]WAY-100635. In this randomized, double-blind, longitudinal study, 30 postmenopausal women underwent treatment with either a combination of oral 17?-estradiol valerate and micronized progesterone (group 1, n=10), oral 17?-estradiol valerate (group 2, n=10), or placebo (group 3, n=10). Two PET measurements were performed, one the day before treatment start and the second after at least eight weeks of treatment. Plasma levels of estradiol (E2), progesterone (P4), sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), follicle stimulating hormone (FSH) and luteinizing hormone (LH) were collected prior to PET measurements. As expected, hormone replacement therapy led to a significant increase in E2 and P4 plasma levels in group 1 and to a significant increase in E2 levels in group 2. The 5-HT1A receptor binding did not change significantly after estrogen, combined estrogen/progesterone treatment or placebo in any of the investigated brain regions. There were no significant correlations between changes in E2 or P4 values and changes in 5-HT1A receptor binding. Although we were not able to confirm effects of gonadal hormone treatment on 5-HT1A receptor binding, our data do not preclude associations between sex steroid levels and serotonin, the neurotransmitter implicated most strongly in the pathogenesis of affective and anxiety disorders. ClinicalTrials.gov Identifier: NCT00755963. © 2014 Elsevier Ltd.
Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalPsychoneuroendocrinology
Volume45
DOIs
Publication statusPublished - 1 Jan 2014
Externally publishedYes

Keywords

  • Estradiol
  • Hormone replacement therapy
  • Positron emission tomography
  • Postmenopausal
  • Progesterone
  • Serotonin-1A receptor

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Endocrine and Autonomic Systems
  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this